# Instructions to Authors -2011 INDIAN JOURNAL OF NOVEL DRUG DELIVERY (IJNDD)

#### AIMS AND SCOPE

Indian Journal of Novel Drug Delivery (IJNDD) is an official publication of Karnataka Education and Scientific Society, Hubli (INDIA). Manuscripts submitted to the journal are accepted on the understanding that: (1) they are subject to editorial review and (2) they have not been and will not be published in whole or in part in any other journal.

The IJNDD is a peer-reviewed quarterly journal, publishes innovative papers, reviews, mini-reviews, rapid communications and notes dealing with physical, chemical, biological, microbiological and engineering studies related to the conception, design, production, characterization and evaluation of drug delivery systems *in vitro* and *in vivo* with strong emphasis on originality and scientific quality.

#### **TYPES OF MANUSCRIPTS**

**Original Research Papers** contain innovative, hypothesis-driven research that is supported by sound experimental design, methodology, and data interpretations.

**Reviews**, usually by invitation and organized into *themed* issues, report on recent advances in pharmaceutical research.

**Mini-Reviews** discuss a more narrowly focused topic of recent research. Unsolicited reviews are considered only if they are authored by investigators who have demonstrated expertise in the relevant areas.

**Rapid Communications** provide a venue for fastbreaking research updates or other news items. The justification for rapid communication should be stated in the cover letter during submission.

**Brief Technical Notes**, normally more limited in scope than the Original Research Papers, must be of high quality, general interest, and sufficient importance to warrant publication.

**Regulatory Notes** provide a summary of regulatory decisions made and rationale for the regulatory decision made on a product. These notes are typically submitted by invitation only, but Authors may propose notes to the Editors.

#### SUBMISSION OF MANUSCRIPTS

Submission of a manuscript to IJNDD for publication implies that the same work has not been published, nor under consideration for publication or in press elsewhere. Authors who fail to adhere to this condition will be charged with all costs that IJNDD incurs and their papers will not be published.

Author publishing results from in-vivo experiments involving animal or humans should state whether due permission for conduct of these experiments was obtained from the relevant authorities/Ethics committee/Institutional Review Board.

Manuscripts will be subjected to peer review process to determine their suitability for publication provided they fulfill the requirements of the journal. After the review, manuscript will be returned for revision along with reviewer's and /or editor's comments. One original copy of the final revised manuscript should be submitted for publication within one month receiving the comments.

**Submission in electronic format:** The authors are strongly encouraged to send their manuscript through e-mail as an attachment as Original/Zip files in MS Word format.

#### **PREPARATION OF MANUSCRIPTS**

Manuscripts must be prepared in accordance with "Uniform requirements for Manuscripts submitted to Biomedical Journal" developed by International Committee of Medical Journal Editors (October 2001).

Manuscripts should be written in clear and concise English, bearing in mind that English is not the native language of many readers. Terminologies that are not generally understood should be avoided; however if it is absolutely necessary to use such terms, they must be defined.

Manuscripts should be typewritten in double-space in A4 size sheets, only on one side, with a 2 cm margin on all sides. Research Papers should have more than 15 pages, Review Articles in the range of 15-30 pages and Short Communications up to 15 pages inclusive of illustrations. Pages should be numbered consecutively, starting with the title page and the matter arranged must be in the following order: Title page, Abstract, Introduction, Materials and Methods, Results, Discussion or Results and Discussion. Conclusion, Acknowledgements, References, Illustrations (pictures, designs, figures, images, graphics, diagrams, photographs and chemistry schemes) and Tables along with captions and legends. Abstract should start on a separate page and each table or figure should be on separate sheet. All other section titles should be in capital letters while subtitles in each section shall be in bold face lower case followed by a colon. No abbreviations or acronyms shall be used in the Title or Abstract acronyms, except for measurements.

All the references, figures (Fig.) and tables (Table) in the text shall be numbered consecutively as they first appear. No sentence shall start with a numeral. Abbreviations like "&" and "etc" shall be avoided in the paper. There shall not be any decorative borders anywhere in the text including the title page. The entire MS Word document with graphs and illustrations pasted in it shall not exceed 2 MB.

# **Title Page**

Title page should contain title of the paper in bold face, title case (font size 14), names of the authors in normal face, upper case (font size 12) followed by the address (es) in normal face lower case. The author to whom all correspondence be addressed should be denoted by an asterisk mark. The title should be as short as possible and precisely indicate the nature of the work in the communication. Names of the authors should appear as initials followed by surnames for men and one givenname followed by surname for women. Full names may be given in some instances to avoid confusion. Names should not be prefixed or suffixed by titles or degrees. Names should be followed by the complete postal address or addresses with pin code numbers of the place(s), where the research work has been carried out. At the bottom left corner of the title page, please mention "\*Address for correspondence" and provide a functional e-mail address. Address of the corresponding author to whom all correspondence may be sent should be given only if it is different from the address already given under authors' name. Trivial sub-titles such as "Title', 'Author', 'Address' or 'Place of Investigation' shall not be included in the title page. Title page should be aligned centre except for "\* Address For correspondence". Provide a running title or short title of not more than 50 characters.

#### Abstract

Reviews, Mini Reviews, Original Research Articles, and Rapid Communications should require an abstract. The abstract is limited to 250 words or less. For Research Articles, the abstract should include a brief (1 to 2 sentence/s) statement for each of the following sections: Introduction, Methods and Materials, Results and Discussion, and Conclusion written in paragraph form. All abstracts must be written in one paragraph, with no subheadings, equations, tables, reference citations or graphics.

#### **Key-words**

Provide four to ten appropriate key words after abstract preferably from MeSH terms provided by National Library of Medicine.

#### Introduction

The introduction should not be an extensive review of the literature but should refer only to previous work which has a direct bearing on the topic to be discussed.

#### Materials and methods

Materials and methods should be written clearly and in such detail that the work can be repeated by others. Procedural detail that has been published previously should be referred to by citation. When a modified procedure is used, only the author's modifications of the previously published method need to be given in detail. The statistical method and the level of significance chosen shall be clearly stated. IJNDD prefers to publish work that has been subjected to an appropriate statistical test at one level of significance. In animal experimentation, ethical guidelines shall he acknowledged.

#### Results

All findings presented in tabular or graphical form shall be described in this section. The data should be statistically analyzed and the level of significance be stated. Data that is not statistically significant need only to be mentioned in the text, no illustration is necessary. All Tables and figures must have a title or caption and a legend to make them self-explanatory.

## Discussion

The discussion should involve the significant findings presented. Wide digressions are unacceptable because of the limitations of space. Results and discussion of results can also be combined under one section, Results and Discussion.

#### Conclusion

In a separate section, the major findings of the study and their usefulness shall be summarized. This paragraph should address the hypothesis or purpose stated earlier in the paper.

#### Acknowledgments

Acknowledgments should appear on a separate page.

#### References

Authors are responsible for the accuracy and completeness of their references as these will not be checked by the editorial office. References should be numbered consecutively in the order in which they are first mentioned in the text (not in alphabetic order). Identify references in text, tables, and legends by Arabic numerals in superscript in square brackets. The titles of journals should be abbreviated according to the style used in Index Medicus. Use complete name of the journal for non-indexed journals.

The commonly cited types of references are shown here, for other types of references such as electronic media, newspaper items, etc. please refer to ICMJE Guidelines (http://www.icmje.org).

#### Articles in Journals

*Format:* Author(s)(surname initials). Title of article. Name of journal. Year; Vol(issue):page no.

- Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech. 2009;10(1):289-96.
- Wang N, Deng L, Guo S, Yao C, Dong A. Controlled release of Paclitaxel from amphiphilic copolymer hybrid assembly nanoparticles. J Nanosci Nanotechnol. 2009 Mar;9(3):2030-7.

(If more than six authors, the first six shall be listed followed by *et al*)

# **Books and Other Monographs**

*Format:* Author(s) of chapter (surname initials). Title of chapter. In: Editor(s) name, editors. Title of book. Place of publication: Publisher; Year of publication. page numbers

- 1. Roberts LJ, Morrow JD. Analgeic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbart LE, Gilman AG, ed. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10<sup>th</sup> ed. New York: McGraw-Hill; 2001. 687-732.
- Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. 3rd ed. Mumbai: Varghese Publishing House; 1987. p. 182-184, 296-303, 311-312.

#### Government publication/Corporate author

Indian Pharmacopoeia, Vol. 2, Govt. of India, Controller of Publications, New Delhi, 1996, A-100.

#### Patent

Pilgaonkar PS, Rustomjee MT, Gandhi AS, Kelkar AA, Bagde P, inventors; Rubicon Research Pvt. Ltd, assignee. Controlled release formulation. US Patent 20080248107. 2008 Oct 9.

#### Website

*Format:* Author/editor (surname initials). Title [online]. Year [cited year month day]. Available from: URL: World Wide Web page Shreeraj HS, Mitesh JS, Jitendra RS. An Overview on Brain Targeting Drug Delivery System [online]. 2009 [cited 2009 Jan 6]. Available from URL: http://www.pharmainfo.net/reviews/overview-braintargeting-drug-delivery-system

#### Illustrations

The number of illustrations should be limited to the essential. Graphs and bar graphs should preferably be prepared using Microsoft Excel and submitted as Excel graph pasted in Word.

Drawings of chemical structures should as far as possible be produced with the use of a drawing program such as ChemDraw.

Diagrams made with Indian ink on white drawing paper, cellophane sheet or tracing paper with hand written captions or titles will not be accepted.

Photographs should bear the names of the authors and the title of the paper on the back, lightly in pencil. Alternatively photographs and photomicrographs can also be submitted as 'JPEG/TIFF with the resolution of 600 dpi or more' images.

Figure and Table titles and legends should be typed on a separate page with numerals corresponding to the Figure and Table.

Keys to symbols, abbreviations, arrows, numbers or letters used in the illustrations should not be written on the illustration itself but should be clearly explained in the legend.

Legends to figures should make the figures comprehensible without reference to the text.

Illustrations should be free of all identifying information relative to the subject and institution.

All illustrations should be referred to as figures and numbered in Arabic numerals (Fig. 1, 2, etc.)

Please note: Because of technical complications which can arise by converting colour figures to 'grey scale' (for the printed version should you not opt for colour in print) please submit in addition usable black and white prints corresponding to all the colour illustrations.

#### Tables

Each table should have a brief explanatory heading and sufficient experimental detail (following the table body as a footnote) so as to be intelligible without reference to the text. Tables must not resemble the material either in text or illustrations. Short or abbreviated column headings should be used and, if necessary, explained in footnotes, and indicated as <sup>a</sup>, <sup>b</sup>, <sup>c</sup>, etc. Statistical measures of variation, S.D., S.E., etc. should be identified. Tables should be numbered separately in Arabic numerals (Table 1, 2, etc.).

#### Symbols and abbreviations

Abbreviations should be of those well known in scientific literature. In vitro, in vivo, in situ, ex vivo, ad libitum, et al. and so on are two words each and should be written in italics. None of the above is a hyphenated word.

Words such as carrageenan-induced inflammation, paracetamol-induced hepatotoxicity, isoproterenol-induced myocardial necrosis, dose-dependent manner are all hyphenated.

The use of the International System of Units (SI) is recommended. For meter (m), gram (g), kilogram (kg), second (s), minute (m), hour (h), mole (mol), liter (l), milliliter (ml), microliter ( $\mu$ l).

No pluralization of symbols is followed. There shall be one character spacing between number and symbol. A zero has to be used before a decimal. Decimal numbers shall be used instead of fractions.

#### Formulas and equations

Structural chemical formulas, process flow diagrams and complicated mathematical expressions should be very clearly presented. All subscripts, superscripts, Greek letters and unusual characters must be identified. Structural chemical formulas and process flow diagrams should be prepared in the same way as graphs.

# **COPYRIGHT GUIDELINES FOR AUTHORS**

All authors must sign the "Transfer of Copyright" agreement before the article can be published. The copyright transfer covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform, or any other reproductions of similar nature and translations, and includes the right to adapt the article for use in conjunction with computer systems and programs, including reproduction or publication in machinereadable form and incorporation into retrieval systems. Authors are responsible for obtaining from the copyright holder permission to reproduce any figures for which copyright exists. Transfer of copyright agreement forms will be sent to the corresponding author following acceptance of the manuscript.

# **CORRECTING PROOFS AND REPRINTS**

Proofs will be sent to the corresponding author. IJNDD will send PDF/Microsoft Word proofs by e-mail for correction. IJNDD will do everything possible to get the article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all corrections are sent back in ONE communication. Subsequent corrections will not be possible. Only typesetting errors may be corrected; *no changes in, or additions to, the accepted manuscript will be allowed.* Proofs should be returned to IJNDD within 48 hours. No gratis reprints will be provided, but corresponding author will receive a copy of that particular issue in which his/her paper is published.

# FOR FURTHER ENQUIRIES PLEASE WRITE TO:

Editorial Office, Indian Journal of Novel Drug Delivery (IJNDD) C/o Karnataka Education and Scientific Society (KESS), D-408, Shantiniketan, Bhairidevarkoppa, HUBLI-580 025 Karnataka, INDIA.

All enquiries can be made through e-mail: editor.ijndd@gmail.com

# IJNDD

# Indian Journal of Novel Drug Delivery

An Official Publication of Karnataka Education & Scientific Society, Hubli (INDIA)